By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and ...

Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top ...

Generic competition for Promacta, a blood disorder drug, and Tasigna, a leukemia treatment, is adding pressure on ​Novartis to offset those lost sales with newer drugs or dealmaking, the report said.

Novartis Q1 2026 earnings missed as generic competition hit Entresto sales; Kisqali and Pluvicto growth offsets.

NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and ...

(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to ...

Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first ...

Novartis (NVS) stock dropped 2% as Q1 sales missed estimates at $13.11B. Entresto plunged 42% on generics while CEO warns of ...

WASHINGTON, Jan 16 - Novartis (NOVN.S), opens new tab won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic ...

Novartis was unsuccessful in convincing a federal court to block MSN Pharmaceuticals from introducing its own version of Novartis' heart-failure drug Entresto, according to a court decision issued on ...

The pharma company backed its 2026 guidance and raised the prospect of upgrading its mid- to long-term growth outlook as it receives data from multiple drug trials.